RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑485‑5p and releasing TPX2 mRNA

Cui, Shoubin; Cui, Li

doi:10.3892/or.2021.8062

Cited by 5 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study revealed that the inactivated PI3K/AKT pathway could alleviate cisplatin resistance by inhibiting epithelial–mesenchymal transition 35 . Based on the results from my previous studies, 18,19 I confirmed that RHPN1‐AS1 could regulate TPX2 and TOP2A to exert tumorigenic role in OC. Meanwhile, TPX2 and TOP2A were reported to regulate PI3K/AKT pathway in cancers 36,37 .…”

Section: Introductionmentioning

confidence: 80%

“…RHPN1‐AS1 promoted tumorigenesis of cervical cancer by modulating miR‐299‐3p/FGF2 axis 44 . In my previous studies, I proved the positive function of RHPN1‐AS1 in OC progression by sponging miR‐6884‐5p/TOP2A axis 19 or miR‐485‐5p/TPX2 axis 18 . However, I did not explore the relationship between RHPN1‐AS1 and clinical characteristics.…”

Section: Discussionmentioning

confidence: 95%

“… 44 In my previous studies, I proved the positive function of RHPN1‐AS1 in OC progression by sponging miR‐6884‐5p/TOP2A axis 19 or miR‐485‐5p/TPX2 axis. 18 However, I did not explore the relationship between RHPN1‐AS1 and clinical characteristics. Moreover, identifying the role of RHPN1‐AS1 in OC progression is not enough to solve the therapeutic problems in OC.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

Cui

2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Cisplatin resistance is a big challenge for ovarian cancer (OC) therapy. The abnormal expression of long noncoding RNAs (lncRNAs) regulated by N6‐methyladenosine (m6A) modification has been confirmed to play the crucial roles in OC. The aim of this study is to explore the regulatory mechanism of lncRNA RHPN1‐AS1 on OC with cisplatin resistance. Methods The real‐time reverse transcription‐polymerase chain reaction was carried out to confirm the expression of RHPN1‐AS1 and methyltransferase‐like 3 (METTL3) in OC. The effects of RHPN1‐AS1 on cisplatin‐resistant OC cells were identified by cell functional experiments and animal experiment. Western blotting was performed to detect the effect of RHPN1‐AS1 on PI3K/AKT pathway. Moreover, methylated RNA immunoprecipitation and RNA stability assays confirmed the interaction between RHPN1‐AS1 and METTL3. Results RHPN1‐AS1 and METTL3 were confirmed to be overexpressed in OC. After transfecting RHPN1‐AS1 overexpression or RHPN1‐AS1 knockdown vectors into cisplatin‐resistant OC cells, it was found that upregulating RHPN1‐AS1 contributed to cell viability, migration, invasion, and tumor growth in vivo. In addition, RHPN1‐AS1 could enhance the protein levels of PI3K and phosphorylated AKT in cisplatin‐resistant OC cells, and METTL3 could enhance the stability of RHPN1‐AS1 by the m6A modification. Conclusion Overall, this study revealed that METTL3‐mediated m6A modification of RHPN1‐AS1 accelerates cisplatin resistance in OC by activating PI3K/AKT pathway.

show abstract

Section: Introductionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

Cui

2022

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…TPX2 is a microtubule-associated protein that directs the kinesin Xklp2 to mitotic spindle poles [20,21], and it plays a vital role in the formation of the microtubules that make up the spindle [22]. TPX2 is overexpressed in esophageal cancer, colorectal cancer, hepatocellular carcinoma, colon cancer, bladder cancer, clear cell renal carcinoma, pancreatic cancer, ovarian carcinoma, breast cancer, and neuroblastoma, and its degree of expression has been associated with poor prognoses [23][24][25][26][27][28][29][30][31][32]. Combined with its critical role as a mitotic regulator, this association implicates TPX2 as a potential oncogene.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Analysis of the Oncogenic Role of Targeting Protein for Xklp2 (TPX2) in Human Malignancies

et al. 2022

View full text Add to dashboard Cite

Mitosis and spindle assembly require the microtubule-associated protein Xenopus kinesin-like protein 2 (TPX2). Although TPX2 is highly expressed in several malignant tumor forms, little is known about its role in cancer. In this study, we performed the gene set enrichment analysis of TPX2 in 33 types of cancers and an extensive pan-cancer bioinformatic analysis using prognosis, tumor mutational burdens, microsatellite instability, tumor microenvironment, and immune cell infiltration data. According to the differential expression study, TPX2 was found to be overexpressed across all studied cancer types. Based on the survival analysis, increased TPX2 expression was associated with a poor prognosis for most cancers. The TPX2 expression level was confirmed to correlate with the clinical stage, microsatellite instability, and tumor mutational burden across all cancer types. Furthermore, TPX2 expression has been linked to tumor microenvironments and immune cell infiltration, particularly in bladder urothelial carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. Finally, the gene set enrichment analysis implicated TPX2 in the regulation of aminoacyl tRNA biosynthesis, which is the most important tumor cell cycle signaling pathway. This comprehensive pan-cancer analysis shows that TPX2 is a prognostic molecular biomarker for most cancers and suggests its potential as an effective therapeutic target for the treatment of these diseases.

show abstract

“…In ovarian cancer, TPX2 mRNA and protein expression levels are elevated in ovarian cancer tissues compared to normal ovarian tissues. TPX2 expression levels are elevated in SKOV3 cells and its overexpression upregulates the expression of Polo-like kinase 1 which in turn leads to cancer cell proliferation and migration [39] .Another study showed that RHPN1-AS1 was expressed at elevated Volume 4 Issue 8 2022 Issue 9 2022 levels in ovarian cancer tissues and cells compared to normal ovarian tissues and cells, and that its overexpression downregulated miR-485-5p expression leading to TPX2 overexpression, which in turn promoted the proliferation, migration and adhesion of ovarian cancer cells and inhibited apoptosis, whether this mechanism works in vivo remains to be investigated [40].…”

Section: Tpx2 and Other Malignanciesmentioning

confidence: 99%

Research Progress of TPX2 on Spindle Assembly and Tumor

2022

JCMP

View full text Add to dashboard Cite

TPX2 is a conserved microtubule-associated protein that plays an important role in regulating cell cycle and mitosis. TPX2 promotes mitotic TPX2 promotes mitotic spindle assembly in a RanGTP-dependent manner, and its overexpression interferes with spindle microtubule formation, resulting in genomic TPX2 is overexpressed in breast cancer, cervical cancer, pancreatic cancer, and other malignant tumors, which promotes tumorigenesis by TPX2 is overexpressed in breast cancer, cervical cancer, pancreatic cancer, and other malignant tumors, which promotes tumorigenesis by leading to abnormal centrosome amplification, aneuploid formation and malignant transformation of cells. Blocking TPX2 expression inhibits tumor cell growth. This paper reviews the molecular structure of TPX2, this paper reviews the molecular structure of TPX2, its role in spindle assembly and its effects on tumor proliferation, invasion and apoptosis, to provide new ideas for TPX2 in tumor diagnosis and clinical target therapy.

show abstract

RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑485‑5p and releasing TPX2 mRNA

Cited by 5 publications

References 50 publications

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

Comprehensive Analysis of the Oncogenic Role of Targeting Protein for Xklp2 (TPX2) in Human Malignancies

Research Progress of TPX2 on Spindle Assembly and Tumor

Contact Info

Product

Resources

About